Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe genetic arrhythmogenic disorder characterized by adrenergically induced ventricular tachycardia (VT) manifesting as syncope and sudden death.
Features include very common findings: Ventricular tachycardia; and common findings: Cardiac arrest, Palpitations, Vertigo, and Supraventricular tachycardia and others. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 7 | Ventricular tachycardia, Cardiac arrest, Supraventricular tachycardia |
Ears | 1 | Vertigo |
Age of onset: at birth.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease characterized by cardiac electrical instability exacerbated by acute activation of the adrenergic nervous system. If untreated the disease is highly lethal, as approximately 30% of those affected experience at least one cardiac arrest and up to 80% have one or more syncopal spells. Few clinical studies have contributed to the understanding of the natural history of CPVT. The main clinical manifestation of CPVT is episodic syncope occurring during exercise or acute emotion. The underlying cause of these episodes is the onset of fast bidirectional or polymorphic ventricular tachycardia (VT).
Spontaneous recovery may occur when these arrhythmias self-terminate;
OR
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Catecholaminergic polymorphic ventricular tachycardia (CPVT) should be suspected in individuals who have one or more of the following :
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Short-coupled ventricular tachycardia (SC-torsade de pointes [TdP]) is a clinical entity presenting with life-threatening polymorphic ventricular arrhythmias resembling in part the pattern of arrhythmias observed in individuals with catecholaminergic polymorphic ventricular tachycardia (CPVT). SC-TdP presents with polymorphic ventricular tachycardia (VT) occurring in the setting of a structurally normal heart and in the absence of any overt baseline EKG abnormality. However, the onset of SC-TdP is not clearly related to adrenergic stimuli (exercise or emotion) and is not associated with the typical bidirectional pattern of CPVT-related tachycardia.
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Biomarker and diagnostic research for catecholaminergic polymorphic ventricular tachycardia has been reported in the published literature.
No approved treatments are currently available for catecholaminergic polymorphic ventricular tachycardia. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for catecholaminergic polymorphic ventricular tachycardia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for catecholaminergic polymorphic ventricular tachycardia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate | 4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate | RyCarma Therapeutics, Inc. | 2020 | — | Designated |
adeno-associated viral vector serotype 8 containing the human cardiac calsequestrin gene | adeno-associated viral vector serotype 8 containing the human cardiac calsequestrin gene | Solid Biosciences Inc. | 2014 | — | Designated |
To establish the extent of disease and needs in an individual diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Recommended Evaluations Following Initial Diagnosis in Individuals with Catecholaminergic Polymorphic Ventricular Tachycardia
System/Concern | Evaluation | Comment
| Resting EKG | Baseline
Holter monitoring | To assess arrhythmias that develop when heart rate
Exercise stress test1 | Baseline for diagnosis monitoring of therapy
Echocardiogram /or MRI | To evaluate for structural defects
Genetic
counseling | By genetics professionals2 | To inform affected persons their families re nature, MOI, implications of CPVT to facilitate medical personal decision making
CPVT = catecholaminergic polymorphic ventricular tachycardia; MOI = mode of inheritance
1. Exercise stress test should be performed until maximal tolerated effort, as some individuals have high heart rate threshold for induction of arrhythmias.
2. Medical geneticist, certified genetic counselor, certified advanced genetic nurse
Competitive sports and other strenuous exercise are always contraindicated for individuals with CPVT. All individuals showing exercise-induced arrhythmias should avoid physical activity, except for light training for those individuals showing good suppression of arrhythmias on exercise stress testing while on therapy. It is important to note that efficacy needs to be periodically retested . The risk for arrhythmias during sports in individuals who have pathogenic variants in genes associated with CPVT but no clinical phenotype (no exercise-induced arrhythmias) is not known; thus, it may be safest for these individuals to refrain from intense physical activity. Digitalis favors the onset of cardiac arrhythmias as a result of delayed afterdepolarization and triggered activity; therefore, digitalis should be avoided in all individuals with CPVT.
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
8 trials found
Table 6.
Recommended Surveillance for Individuals with Catecholaminergic Polymorphic Ventricular Tachycardia
System/Concern | Evaluation | Frequency
Monitoring
therapy
efficacy | Cardiologist eval to incl:
Resting EKG
Exercise stress test, performed at maximal age-predicted heart rate. For those on beta-blocker therapy (in whom maximal heart rate cannot be reached), test should be performed at highest tolerated workload.
Holter monitoring
Echocardiogram MRI at least every 2 yrs
| • Every 6-12 mos (per severity of clinical manifestations)
Follow-up visits are very important esp until puberty, as body weight rapidly drug dosages must be continually adjusted.
Limitation on
physical activity | • Can be defined on basis of exercise stress test done in hospital setting
Use of commercially available heart rate monitoring devices for sports participation can be helpful in keeping heart rate in safe range during physical activity but should not be considered as alternative to medical follow-up visits.
Since heart rate threshold for onset of arrhythmias is often reproducible in the same person, the advice for allowed exercise intensity should be individualized based on results of exercise stress test.
| Review at each visit.
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Phenotype severity distribution: 1 very common feature, 6 common features.
Estimated prevalence: 1-5 in 10,000 (Uncommon).
8 clinical trials registered, 5 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 2 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06658899](https://clinicaltrials.gov/study/NCT06658899) | A Phase 2 Study of CRD-4730 in CPVT | PHASE2 | Cardurion Pharmaceuticals, Inc. | RECRUITING |
[NCT04189822](https://clinicaltrials.gov/study/NCT04189822) | Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank | — | University of British Columbia | ENROLLING_BY_INVITATION |
[NCT07263139](https://clinicaltrials.gov/study/NCT07263139) | Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | PHASE2 | Agiana Pharmaceuticals | RECRUITING |
[NCT06546137](https://clinicaltrials.gov/study/NCT06546137) | National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry | — | Hospital do Coracao | RECRUITING |
[NCT07148089](https://clinicaltrials.gov/study/NCT07148089) | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | PHASE1 | Solid Biosciences Inc. | RECRUITING |
178 publications have been identified in PubMed for catecholaminergic polymorphic ventricular tachycardia. Research spans Review / Meta-Analysis (26%), Basic Science / Preclinical (22%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 46 | 26% |
Laboratory research | 38 | 22% |
Patient case studies | 35 | 20% |
Disease patterns and progression | 16 | 9% |
Other research | 14 | 8% |
New treatment approaches | 13 |
Oudit GY (2026). [PMID: 41905648](https://pubmed.ncbi.nlm.nih.gov/41905648/). *Can J Cardiol*. [Other]
Sharma V (2026). [PMID: 41694040](https://pubmed.ncbi.nlm.nih.gov/41694040/). *World J Cardiol*. [Review / Meta-Analysis]
Farzam K (2026). [PMID: 30969530](https://pubmed.ncbi.nlm.nih.gov/30969530/). *Unknown Journal*. [Basic Science / Preclinical]
Naderi B (2026). [PMID: 41949873](https://pubmed.ncbi.nlm.nih.gov/41949873/). *JAMA Cardiol*. [Diagnostic / Biomarker]
Manolis TA (2026). [PMID: 41350148](https://pubmed.ncbi.nlm.nih.gov/41350148/). *Eur J Intern Med*. [Review / Meta-Analysis]
Ohno S (2026). [PMID: 41550621](https://pubmed.ncbi.nlm.nih.gov/41550621/). *J Cardiol Cases*. [Case Report / Case Series]
Striessnig J (2026). [PMID: 42126403](https://pubmed.ncbi.nlm.nih.gov/42126403/). *J Gen Physiol*. [Basic Science / Preclinical]
Küçüker H (2026). [PMID: 41961118](https://pubmed.ncbi.nlm.nih.gov/41961118/). *Turk Kardiyol Dern Ars*. [Case Report / Case Series]
Koc Buyuker A (2026). [PMID: 41265537](https://pubmed.ncbi.nlm.nih.gov/41265537/). *Cardiovasc Pathol*. [Basic Science / Preclinical]
Zou R (2026). [PMID: 41987505](https://pubmed.ncbi.nlm.nih.gov/41987505/). *Cardiol Young*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 6:21 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Management of CPVT is summarized in a specific consensus document from the Heart Rhythm Association (HRS) and the European Heart Rhythm Association (EHRA) (full text), and in the recent version of the European Society of Cardiology (ESC) guidelines on ventricular arrhythmias (full ...
Source: GeneReviews — "Catecholaminergic Polymorphic Ventricular Tachycardia"
Testing and diagnosis research | 8 | 5% |
Clinical study results | 6 | 3% |
AI-curated news mentioning catecholaminergic polymorphic ventricular tachycardia
Updated Apr 10, 2026
A novel RYR2-A4510T variant has been identified, presenting both as autosomal dominant and autosomal recessive forms of catecholaminergic polymorphic ventricular tachycardia. This discovery enhances understanding of the genetic underpinnings of this arrhythmia.
A recent study evaluates missense variants in the RYR2 gene associated with catecholaminergic polymorphic ventricular tachycardia (CPVT). The research provides continuous Bayesian estimates of penetrance, enhancing understanding of genetic risk factors in this rare cardiac condition.